2-甲基-缬氨酸 | 26287-62-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-甲基-缬氨酸
• 中文别名: 2-甲基缬氨酸
• 英文名称: α-methylvaline
• 英文别名: 2-amino-2,3-dimethylbutanoic acid；DL-α-Methylvalin；L-2-amino-2,3-dimethylbutyric acid；2-azaniumyl-2,3-dimethylbutanoate
• CAS: 26287-62-7
• 化学式: C₆H₁₃NO₂
• 分子量: 131.175
• InChiKey: GPYTYOMSQHBYTK-UHFFFAOYSA-N

物化性质

• 熔点：
  293 °C (sublm)
• 沸点：
  217.7±23.0 °C(Predicted)
• 密度：
  1.038±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -1.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2922499990
• 危险性防范说明：
  P233,P260,P261,P264,P270,P271,P280,P301+P312,P302+P352,P304,P304+P340,P305+P351+P338,P312,P321,P330,P332+P313,P337+P313,P340,P362,P403,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Amino-2,3-dimethylbutanoic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Amino-2,3-dimethylbutanoic acid
CAS number: 26287-62-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H13NO2
Molecular weight: 131.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-甲基-缬氨酸 在 乙酸酐 作用下， 以 sodium hydroxide 为溶剂， 生成 2-acetylamino-2,3-dimethylbutyric acid
  参考文献：
  名称：

  Imidazoisoindolediones and the use thereof as herbicidal agents

  摘要：

  该发明涉及包括其光学异构体在内的新型咪唑异异吲哚二酮化合物。该发明还涉及使用咪唑异异吲哚二酮及其光学异构体控制不良植物物种的方法，以及制备这些化合物的过程。

  公开号：

  US04017510A1
• 作为产物：
  描述：

  5-methyl-5-(1-methylethyl)imidazolidine-2,4-dione 在 barium dihydroxide 作用下， 生成 2-甲基-缬氨酸
  参考文献：
  名称：

  Armstein; Margreiter, Biochemical Journal, 1958, vol. 68, p. 339,340,341

  摘要：

  DOI：

文献信息

• [EN] ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER<br/>[FR] CONJUGUÉ ANTICORPS-MÉDICAMENT ET SON UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：PF MEDICAMENT

  公开号：WO2015162293A1

  公开（公告）日：2015-10-29

  The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

  本发明涉及一种抗体药物偶联物。从一方面来说，该发明涉及一种抗体药物偶联物，包括一种能够与靶标结合的抗体，所述抗体与至少一种选自多拉司汀10衍生物和奥里司汀衍生物的药物偶联。该发明还包括治疗方法以及使用所述抗体药物偶联物治疗癌症的应用。
• Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
  申请人：——

  公开号：US20040049037A1

  公开（公告）日：2004-03-11

  This invention relates to a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene. The ligands comprise a class of ketones.

  这项发明涉及一种调节外源基因表达的方法，其中包括一个包括：DNA结合结构域；配体结合结构域；转录激活结构域；和配体的ecdysone受体复合物与包括：外源基因和响应元件的DNA构建物接触；其中外源基因受响应元件控制，并且在配体存在的情况下DNA结合结构域与响应元件结合导致基因的激活或抑制。配体包括一类酮。
• New derivatives of resveratrol
  申请人：Mattarei, Andrea

  公开号：EP2774915A1

  公开（公告）日：2014-09-10

  A novel class of derivatives of resveratrol is provided which have favourable physico-chemical properties when compared with resveratrol itself. It is characterized by the presence of three carbamate functions, in which resveratrol is the oxygen-linked moiety, while the nitrogen atom carries a substituent conferring desirable characteristics to the molecule. These new compounds are especially suitable as precursors (prodrugs) and vehicles of resveratrol in preparations used as dietary integrators or in pharmaceutical compositions: they are stable towards oxidative degradation allowing for long shelf lifetimes and have suitable reactivity to regenerate and deliver resveratrol under physiological conditions.

  提供了一类新的白藜芦醇衍生物，与白藜芦醇本身相比，具有有利的理化性质。其特征在于存在三个碳酸酯功能，其中白藜芦醇是氧连接的基团，而氮原子带有赋予分子所需特性的取代基。这些新化合物特别适合作为前药和载体用于作为饮食添加剂或药物组合物中使用的白藜芦醇制剂：它们对氧化降解稳定，允许长的保质期，并在生理条件下具有适当的反应性以再生和输送白藜芦醇。
• [EN] IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER<br/>[FR] CONJUGUÉ ANTICORPS DE L'IGF-1R-MÉDICAMENT ET SON UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：PF MEDICAMENT

  公开号：WO2015162291A1

  公开（公告）日：2015-10-29

  The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug- conjugate for the treatment of cancer.

  本发明涉及一种能够结合IGF-1R的抗体药物偶联物。从一方面来说，该发明涉及一种抗体药物偶联物，包括一种能够结合IGF-1R的抗体，所述抗体与至少一种选自多拉司汀10衍生物和奥里司汀衍生物的药物偶联。该发明还包括治疗方法以及使用所述抗体药物偶联物治疗癌症的方法。
• [EN] CONJUGATE OF MONOMETHYL AURISTATIN F AND TRASTUZUMAB AND ITS USE FOR THE TREATMENT OF CANCER<br/>[FR] CONJUGUÉ DE MONOMÉTHYLE AURISTATINE F ET DE TRASTUZUMAB ET SON UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：PF MEDICAMENT

  公开号：WO2016173682A1

  公开（公告）日：2016-11-03

  The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody consisting of the Trastuzumab, said antibody being conjugated to at least one drug consisting of a monomethyl auristatin F derivative. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

  本发明涉及一种抗体药物偶联物。从一方面来说，该发明涉及一种抗体药物偶联物，包括由曲妥珠单抗组成的抗体，所述抗体与至少一种由单甲基奥瑞他汀F衍生物组成的药物偶联。该发明还包括治疗方法和使用所述抗体药物偶联物治疗癌症的方法。